Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120007/S034

Aptima HPV 16 18/45 Genotype Assay

Gen-Probe Incorporated · Decision date Feb 3, 2026

FDA DECISIONP120007/S034

What did the FDA approve?

FDA records P120007/S034 as a supplement to PMA P120007, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Feb 3, 2026.

FDA approval order statement

Approval for the Aptima HPV 16 18/45 Genotype Assay for expanding the indications to include primary screening.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Microbiology
Decision date
Feb 3, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P120007/S034
Regulatory pathway
PMA supplement
Product code
OYB
Decision code
APPR
Decision date
Feb 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Kit, rna detection, human papillomavirus.

Product code
OYB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P120007/S034 received

    Application receipt date recorded by FDA.

  2. P120007/S033 · Related supplement

    Aptima HPV 16 18/45 Genotype Assay (Box 1); Aptima HPV 16 18/45 Genotype Assay (Box 2); Aptima HPV 16 18/45 Genotype Ass

  3. P120007/S034 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P120007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120007

Product / regulatory recordCompanyPathwayDecision dateSource
Gen-Probe IncorporatedPMA supplementOct 7, 2025FDA

Explore the linked device profile

Other records with product code OYB

Product / regulatory recordCompanyPathwayDecision dateSource
APTIMA HPV ASSAYP100042/S038
Gen-Probe IncorporatedPMA supplementFeb 3, 2026FDA
Gen-Probe IncorporatedPMA supplementOct 7, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Gen-Probe Incorporated

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10210 Genetic Center Dr., San Diego, CA, 92121

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records